Skip to main content
Article
What is the Role of Cannabidiol in Refractory Epilepsy
Journal of the American Academy of PAs
  • Kathryn M. LaFleur
  • Eric C. Nemec, Sacred Heart University
Document Type
Peer-Reviewed Article
Publication Date
1-1-2019
Abstract

The FDA recently approved the first cannabidiol oral medication to treat refractory epilepsy in patients with Dravet syndrome and Lennox-Gastaut syndrome. This article describes the safety and efficacy of cannabidiol treatment in patients with refractory epilepsy.

Comments

At the time this article was written, Kathryn M. LaFleur was a student in the PA program at Sacred Heart University.

DOI
10.1097/01.JAA.0000553393.36249.df
PMID
30817475
Pages
16-18
Citation Information

LaFleur, K. & Nemec, E. (2019). What is the role of cannabidol in refractory epilepsy. Journal of the American Academy of PAs, 32(3), 16-18. Doi: 10.1097/01.JAA.0000553393.36249.df